CalciMedica, Inc.
CALC Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.23
KIRA · Stoqly’s AI analyst, in plain words
- CalciMedica, Inc. had $0.7M of revenue in fiscal 2025, down 29.7% on the year before.
- Its operating margin was −3,242.8%, down 855.8 pts: of every 100 in sales, about −3,243 is left after running the business.
- CalciMedica, Inc. lost $29.6M in fiscal 2025.
- Free cash flow was −$21.2M in fiscal 2025, −2,974.2% of revenue.
Market cap
$21.0M
P/E
—
Revenue
$0.7M
Net income
−$29.6M
Free cash flow
−$21.2M
Operating margin
−3,242.8%
CalciMedica, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−29.7%
No. Sales fell 29.7% last year.
Does it make a profit?
−4,146.1%
No. It lost money last year.
Does profit turn into cash?
−2,974.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What CalciMedica, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 3, 2026
- Legal name
- CalciMedica, Inc.
- CIK
- 0001534133
CalciMedica, Inc. · CALC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | — | $1.0M | $0.7M |
| Revenue growth | — | — | — | — | −29.7% |
| Operating margin | — | — | — | −2,387.0% | −3,242.8% |
| Net income | −$35.8M | −$7.8M | −$34.4M | −$13.7M | −$29.6M |
| Net margin | — | — | — | −1,351.1% | −4,146.1% |
| Diluted EPS | −$1.69 | −$111.16 | −$7.66 | −$1.22 | −$1.97 |
| Cash | |||||
| Cash from operations | −$31.5M | −$11.8M | −$25.7M | −$21.1M | −$21.2M |
| Capital expenditure | $0.5M | $0.0M | $0.1M | $0.0M | $0.0M |
| Free cash flow | −$32.0M | −$11.8M | −$25.8M | −$21.2M | −$21.2M |
| FCF margin | — | — | — | −2,086.2% | −2,974.2% |
| Share count change | 220.3% | −99.6% | 5,357.8% | 150.7% | 33.5% |
| Debt and strength | |||||
| Cash and short-term investments | $63.7M | $1.3M | $11.2M | $18.7M | $13.0M |
| Shareholders' equity | −$64.0M | −$71.3M | $8.2M | $14.4M | −$6.6M |
| Current ratio | 16.5x | 0.4x | 2.9x | 5.3x | 3.6x |
| Interest coverage | — | — | — | — | −16.3x |
| Returns and quality | |||||
| Return on equity | −232.6% | — | — | −121.4% | −761.0% |
| Return on tangible equity | — | — | −421.2% | −95.1% | — |
| Piotroski F-score | — | — | — | — | 2 |
| Altman Z'' | −22.0 | −149.1 | −53.9 | −26.4 | −52.5 |
Insiders bought, 12 months
$0.2M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
CalciMedica, Inc. · CALC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.23 a share, the company is worth $21.0M.
Source: SEC EDGAR XBRL filings (CIK 0001534133). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.